Pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Tuesday that it achieved net income of USD28.7m (USD0.75 per diluted share) for its fiscal year ended 30 June 2018.
This reflects an improvement when compared with net loss of USD0.6m (USD0.02 per share) for fiscal 2017.
GAAP net sales of USD684.6m were recorded for fiscal 2018, up from GAAP net sales of USD637.3m for fiscal 2017.
For fiscal 2017, R&D expenses were USD29.2m, a decline over R&D expenses of USD42.1m for fiscal 2017.
C-Rad posts increased result in Q4 2018
Regeneron posts higher GAAP net income of USD2.444bn for 2018
Lannett announces record net sales of USD193.7m in Q2 fiscal 2019; increases fiscal 2019 outlook
Coloplast's profit up by 5% in Q1 2018/19
Neurocrine Biosciences achieves higher net income of USD21.1m for 2018
Stellar Biotechnologies incurs Q1 net loss of USD1.41m
Gilead Sciences reports 11% rise in Q1 2019 dividend
Senseonics extends distribution agreement with Roche Diabetes Care
Orexo reports financial results for Q4 2018
AstraZeneca reports completion of divestment of US Synagis rights to Sobi